ARA-290

Research Phase

ARA-290 (Cibinetide)

Aliases
Cibinetide, pHBSP
Administration
Subcutaneous injection

Documented benefits

Tier 1 · Peer-reviewed / regulatory

Benefit categories

Recovery & Healing

ARA-290's defining research application — isolating erythropoietin's tissue-protective effect from its blood-doping-relevant activity.

Nerve protection

Its core, defining mechanism — selectively activating a tissue-protective receptor pathway distinct from the one responsible for red blood cell production.

Anti-inflammatory

Suppresses spinal microglia and inflammatory macrophage activity specifically in damaged nerve tissue.

Pain reduction

Produced significant, long-lasting reduction in nerve-injury-related pain sensitivity in controlled animal studies.